Abstract：Objective To explore the effect of exenatide in treatment of obesity type 2 diabetesmellitus patients whose blood glucose can not be controlled well by mximum dose.Methods The retrospective analysis of 40 cases of patients from December 2014 to December 2015 in our hospitalwere randomly divided into two groups according to digital random tablemethod.Exenatide was used in the experimental group and insulin inth control group.The changes in the levels of fasting blood glucose，two-hour postprandial blood glucose，fasting C-peptide and hemoglobin A1c（HbA1c）were observed at the twelve weeks.Results The blood glucose and HbA1c of the two groups decreased at the twelve weeks （P＜0.05）.BMI decreased in the experimental group and increased in the control group（P＜0.05）.The HOMA-IR of the two groups decreased and wasmore obvious in the experimental group than that in the control group（P＜0.05）.No hypoglycemia happened in the experimental group.Conclusion Exenatide can reduce blood glucose and body weight efficiently.And it can improve the sensitivity of insulin at the same time.
丁晓慧. 艾塞那肽治疗肥胖型2型糖尿病的效果观察[J]. 中国当代医药, 2016, 23(25): 78-80.
DING Xiao-hui. The efficacy observavtion of exenatide therapy for patient with obesity type 2 diabetesmellitus. 中国当代医药, 2016, 23(25): 78-80.
Klein S，Sheard NF，Pi-Sunyer X，et al.Weightmanagement through life style modification for the prevention and management of type 2 diabetes：rationale and strategies［J］.Diabetes Care，2004，27（8）：2067-2073.
Nielsen LL，Young AA，Parkes DG.Pharmacology of exenatide （synthetic exendin-4）：a potential therapeutic for improved glycemic control of type 2 diabetes［J］Regul Pept，2004，117 （2）：77-88.
［6］
Stoffers DA，Kieffer TJ，Hussain MA，et al.Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeomain protein IDX-1 and increase islet size in mouse pancreas［J］.Diabetes，2009，49（5）：741-748.
［7］
Klinger S，Poussin C，Debril MB，et al.Increasing GLP-1 induced beta-cell proliferation by silencing the negative regulators of signaling cAMP respinse elsmentmodulatoralpha and DUSP14［J］.Diabetes，2008，57（3）：584-593.
［8］
Pamaud G，Bosco D，Berney T，et al.Effects of exenatide （exenatide-4）on glycemic controland weightover 30 weeks in metformin treated patients with type 2 diabetes［J］.Diabetes Care，2005，28（1）：1092-1100.
Buse JB，Rosenstock J，Sesti G，et al.Liraglutide once a day versus exenatide twice a day for type 2 diabetes：a 26-week randomised，parallel-group，multinational，openlabel trial（LEAD-6）［J］.Lancet，2009，374（9683）：39-47.
［11］
Gautier JF，Chouken SP，Girard J.Physiology of incretins （GIP and GLP-1）and abnormalities in type 2 diabetes［J］. Diabetes Metab，2008，34（Suppl 2）：S65-S72.
Tahrani AA，Bailey CJ，Del Prato S，et al.Management of type2 diabetes：new and future developments in treatment［J］. Lacent，2011，378（9786）：182-197.
［13］
Bolen S，Feldaman L，Vassy J，et al.Systematic review：comparative effectiveness and safety of oralmedication for type 2 diabetesmellitus［J］.Ann Iner Med，2007，147（6）：386-399.
京公网安备 11010502046607号